NAINH · The Development of Mechanism-Based Inhibitors of Influenza Neuraminidase to target Drug Induced Resestance
7РП — „Хора“ (Действия „Мария Кюри“)
- Период
- 2009-06-01 → 2011-05-31
- Финансиране от ЕС
- 171 868 €
- Участници
- 1
- Схема
- MC-IEF
Линиите свързват координатора с партньорите.
Накратко на български
Нови химични съединения, базирани на сиални киселини, се тестват като инхибитори на ензима невраминидаза при грипните вируси. Това помага за разбирането на механизмите, чрез които вирусите развиват устойчивост към лекарствата и как да се създадат по-ефективни средства за борба с тях.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
The Development of Mechanism-Based Inhibitors of Influenza Neuraminidase to target Drug Induced Resestance
Project objectives According to the original proposal and the Annex I of the Grant Agreement, the research and training objectives of the present project were divided into four main areas: carbohydrate synthesis, catalyst design, inhibition kinetics and virus inhibition (at CSIRO). Project results Following our planned work, during the initial part of the project the researcher focused on the synthesis of 2,3-difluoro sialic acids with axial amino functionalities introduced at carbon-4. In order to obtain those derivatives, she developed novel synthetic methods for Pd(0) catalysed allylic amination of sialic acid. Furthermore, novel fluorine containing sialic acids were generated through the modification of literature protocols. In relation to the fluorination reactions, an in-depth study of different derivatives of sialic acid was carried out with different substituents and configurations at carbon-4, and a variety of fluorination methods developed to control the stereo-selectivity of this reaction, permitting production of the different isomers with excellent enantio-selectivities. Following the successful synthesis of target compounds, the researcher performed the kinetic evaluation of inhibitors towards influenza virus. A number of kinetic inhibition values were obtained which have provided essential information about the mechanism of binding these compounds with influenza neuraminidase. Doubtless, these encouraging initial results have opened new research lines within the group. In collaboration with one of the world's eminent influenza virologists at CSIRO (Australia), virus inhibition studies were carried out against a panel of wild-type and drug-resistant mutant strains of influenza neuraminidase to check their activity across a range of influenza serotypes and the capacity of these compounds to be selective towards influenza neuraminidase over human neuraminidases. In addition, X-ray crystal structures of several inhibitors in complex with influenza neuraminidase were also obtained at CSIRO, providing insight into their structure-activity relationship. Dissemination of results and project impact As was planned in the initial proposal, the results obtained from the project have been presented at national and international conferences and will be published in high-impact international journals. As for participation in conferences, the researcher has participated in five major national and international conferences, including two poster presentations. As for the research training, the researcher received initial training from the university's technical staff (MNR, Mass Spectrometry, HPLC, etc.) after which she developed most of her research work independently. Furthermore, she received training in enzyme kinetics and enzymology from Dr Andrew Watts. Group and literature meetings took place during the two-year period helping to focus the research work and to identify new research areas of potential interest, as well as helping to enhance the researcher's knowledge of chemistry. She also presented numerous group meetings and written reports to extend and clarify the results obtained. During these group meetings the results obtained were presented as a lecture and concluded with an open discussion of ideas with group members. At the same time, the fellow was also involved in presenting workshops and tutorials to undergraduate students for the Department of Pharmacy, and supervised three undergraduate final-year students, three PhD students and a Masters student. To summarise, the excellent research results obtained together with the very good quality of the training and new skills acquired by the researcher provided her with an exceptional opportunity to develop professional maturity, diversity, independence and leadership qualities.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
The recent emergence of the highly pathogenic H5N1 strain of avian influenza now circulating in Asia, EU and Africa has increased concerns that a new, and devastating, influenza pandemic may be imminent. Antiviral drugs represent the first line of defence for pandemic outbreaks, and governments are currently stockpiling the influenza neuraminidase inhibitors Relenza® (Zanamivir) and Tamiflu® (Oseltamivir) in preparedness. These neuraminidase inhibitors are highly potent and specific inhibitors against all known influenza A and B strains, including the avian H5N1 virus. There are, however, several problems associated with Relenza and Tamiflu. Unfortunately, as Relenza is only delivered to the respiratory tract, its usefulness is limited if the pandemic influenza strain spreads to other organs, and, more alarmingly, drug-induced resistance to Tamiflu has already been observed in clinical isolates from H5N1 infected patients. As such, there is an urgent need to develop new and improved classes of anti-virals for the treatment of influenza. Dr Watts has recently filed a provisional patent application for the use of fluorinated sialic acid analogues as ‘mechanism-based’ neuraminidase inhibitors for the treatment of influenza. These novel compounds are known to covalently inhibit influenza neuraminidases by specifically targeting amino acid residues essential for catalytic activity and, as such, drug-induced resistance is less likely to evolve in response to these compounds. We propose to synthesise a series of modified fluoro-sialic acids as ‘mechanism-based’ inhibitors of influenza neuraminidases, incorporating structural features designed to improve the pharmacokinetic properties and inhibitory activities of the original inhibitors. We will then perform detailed kinetic analyses of their inhibitory activity against purified influenza neuraminidases, and potent inhibitors will then be tested for efficacy towards a panel of wild-type and drug-resistant influenza viruses.
Оригинален текст от CORDIS (на английски).
Участници
- UNIVERSITY OF BATH · BATHКоординаторОбединеното кралство
Връзки
Данни: CORDIS, © Европейски съюз
